How long should I take erdafitinib? Standard course of treatment and effects of long-term use

Erdafitinib is an oral targeted drug for patients with bladder cancer and other patients who carry FGFR gene mutations. Its standard treatment course is usually formulated by doctors based on the patient's specific conditions. Under normal circumstances, the recommended dose is 8mg (once a day), which should be adjusted according to the patient's tolerance after continuous administration for 21 days. Some patients may need to increase to 9mg. During treatment, doctors will regularly evaluate the efficacy and side effects of the drug to decide whether to adjust the dose or continue taking the drug.

Standard treatment cycles vary depending on the patient's condition. For patients receiving erdafitinib for the first time, if the drug shows positive effects within weeks or months, it is generally recommended to continue taking it until disease progression or intolerable adverse effects occur. If the patient's condition is stable and the drug is well controlled, long-term use may bring about a more durable survival benefit. But if the disease progresses or the patient experiences severe side effects, doctors may stop using it or switch to another treatment.

Long-term use of erdafitinib may cause some side effects, such as hyperphosphatemia, ocular toxicity, fatigue, oral ulcers, diarrhea, etc. Among them, hyperphosphatemia is the more common problem and needs to be managed through dietary control or drug intervention. In addition, since long-term medication may affect kidney function, liver function, and eye health, patients need to undergo regular blood tests and eye examinations to monitor the effects of the medication on the body.

In general, the taking time of erdafitinib depends on the individual condition. Some patients may need long-term use to maintain the efficacy, while for patients with intolerance or disease progression, the regimen may need to be adjusted in advance. Therefore, patients need to maintain close communication with their doctors during treatment and regularly evaluate the efficacy and side effects of the medication to ensure the safety and effectiveness of the medication.

Reference link:https://www.balversa.com/